Metoprolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension and Angina Pectoris
暂无分享,去创建一个
R. N. Brogden | R. Heel | T. Speight | G. Avery | R. C. Heel | T. M. Speight | G. S. Avery
[1] R. Johansson,et al. Combined pharmacokinetic and pharmacodynamic studies of metoprolol in the cat and the dog. , 2009, Acta pharmacologica et toxicologica.
[2] G. Johnsson,et al. Effects of metoprolol and propranolol on furosemide-stimulated renin release in healthy subjects , 1975, European Journal of Clinical Pharmacology.
[3] O. Keyriläinen,et al. Effects of the cardioselective beta-blocker metoprolol in angina pectoris. A subacute study with exercise tests. , 1975, Annals of clinical research.
[4] B. Åblad,et al. Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. , 1973, Life sciences. Pt. 1: Physiology and pharmacology.
[5] R. Lee,et al. Anti-arrhythmic action of nadolol, a β-adrenergic receptor blocking agent , 1976 .
[6] G. Frithz. Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension. , 1978, Current medical research and opinion.
[7] K. Palmer,et al. Comparison of effects of metoprolol and propranolol on asthmatic airway obstruction. , 1976, British medical journal.
[8] H. Waal-Manning,et al. Hypertension: Which Beta-Blocker? , 1976, Drugs.
[9] B. Prichard,et al. β-Adrenergic Receptor Blocking Drugs in Angina Pectoris , 2012, Drugs.
[10] E. Sowton,et al. Assessment of Metoprolol, a Cardioselective Beta-Blocking Agent, during Chronic Therapy in Patients with Angina Pectoris , 1976, Journal of International Medical Research.
[11] A. Amery,et al. Comparative hemodynamic studies in man of adrenergic bepta-1-receptors agents without (h 93/26 equal to metoprolol) or with (h 87/07) intrinsic sympathicomimetic activity. , 2009, Acta pharmacologica et toxicologica.
[12] H. H. Harms,et al. Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol. , 1978, British journal of clinical pharmacology.
[13] L. Opie,et al. PROPOSED METABOLIC VICIOUS CIRCLE IN PATIENTS WITH LARGE MYOCARDIAL INFARCTS AND HIGH PLASMA-FREE-FATTY-ACID CONCENTRATIONS , 1977, The Lancet.
[14] G. Nyberg,et al. Influence of metoprolol and propranolol on hemodynamic effects induced by physical work and isoprenaline. , 2009, Acta pharmacologica et toxicologica.
[15] L. Savi,et al. The action of β-adrenergic blocking and stimulating agents on insulin secretion. Characterization of the type of β receptor , 1971, Diabetologia.
[16] K. Hoffmann,et al. Metabolism of metoprolol‐(3H) in man, the dog and the rat , 2009 .
[17] H. Wasir,et al. Acute haemodynamic effects of metoprolol in hypertensive patients. , 1977, British journal of clinical pharmacology.
[18] S. Rössner,et al. Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests. , 1976, British heart journal.
[19] B. Ljung,et al. Anti-hypertensive effect of metoprolol in spontaneously hypertensive rats. , 1976, Clinical science and molecular medicine. Supplement.
[20] R. Elofsson,et al. Binding of adrenergic beta-receptor antagonists to human serum albumin. , 1974, Acta pharmaceutica Suecica.
[21] N. Bodin,et al. Tissue distribution of metoprolol-(3-h) in the mouse and the rat. , 2009, Acta pharmacologica et toxicologica.
[22] B. Hansson,et al. Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol , 1977, European Journal of Clinical Pharmacology.
[23] G. Johnsson,et al. Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics , 1975, European Journal of Clinical Pharmacology.
[24] D. Adams,et al. β‐Adrenergic Blockade in Essential Hypertension: Reduced Renin Release Despite Renal Vasoconstriction , 1976, Circulation research.
[25] M. Vallotton,et al. Effect of β‐Blocking Agents and Angiotensin II on Isoproterenol‐Stimulated Renin Release from Rat Kidney Slices , 1977, Circulation research.
[26] G. Johnsson. Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work. , 2009, Acta pharmacologica et toxicologica.
[27] E. Besterman,et al. Relative activity of atenolol and metoprolol. , 1977, British medical journal.
[28] C. Regårdh,et al. Clinical Pharmacokinetics ofβ-Adrenoreceptor Blockers , 2012, Drugs.
[29] K. Hoffmann,et al. Metabolism of metoprolol in the rat in vitro and in vivo. , 1976, Xenobiotica; the fate of foreign compounds in biological systems.
[30] R. Miller,et al. Comparative effects of tolamolol and propranolol on cardiac and peripheral circulatory function in patients with coronary artery disease , 1975, Clinical pharmacology and therapeutics.
[31] D. B. Evans,et al. Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression. , 1975, European journal of pharmacology.
[32] P. Lundborg,et al. Plasma levels and effect on heart rate and blood pressure of metoprolol after acute oral administration in 12 geriatric patients. , 2009, Acta medica Scandinavica.
[33] R. Binkhorst,et al. Effects of adrenaline during treatment with propranolol and metoprolol. , 1977, British medical journal.
[34] E. B. French,et al. Observations in Man of Hypoglycaemia during Selective and Non-Selective Beta-Blockade , 1977, Scottish medical journal.
[35] E. W. Reynolds,et al. Clinical evaluation of glucagon by continuous infusion in the treatment of low cardiac output states. , 1970, American heart journal.
[36] C. Dollery. Closing remarks: current status of labetalol. , 1976, British journal of clinical pharmacology.
[37] C. von Bahr,et al. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension , 1976, Clinical pharmacology and therapeutics.
[38] A. Dahlqvist,et al. Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris. , 1978, Current medical research and opinion.
[39] C. Furberg,et al. Effects of single doses of alprenolol and two cardioselective β-blockers (H 87/07 and H 93/26) on exercise-induced angina pectoris , 2004, European Journal of Clinical Pharmacology.
[40] J. M. Shaw,et al. Metabolic Studies in Patients with Nadolol: Oral and Intravenous Administration , 1977, Journal of clinical pharmacology.
[41] P. Lund-johansen,et al. Haemodynamic long-term effects of beta-receptor-blocking agents in hypertension: a comparison between alprenolol, atenolol, metoprolol and timolol. , 1976, Clinical science and molecular medicine. Supplement.
[42] C. Dahlöf,et al. Cardiac effects of beta-adrenergic receptor antagonists. , 1974, Advances in cardiology.
[43] H. Waal-Manning. Metabolic Effects ofβ-Adrenoreceptor Blockers , 1976, Drugs.
[44] S. Rosengård. Antihypertensive Effect and Tolerability of Metoprolol during Long-Term Treatment: A Multicentre Study , 1977, The Journal of international medical research.
[45] C. Bengtsson. The effect of metoprolol --a new selective adrenergic beta1-receptor blocking agent-- in mild hypertension. , 2009, Acta medica Scandinavica.
[46] Dollery Ct. Closing remarks: current status of labetalol. , 1976 .
[47] N. Svedmyr,et al. Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics , 1976, European Journal of Clinical Pharmacology.
[48] C. Regårdh,et al. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long‐term treatment , 1975, Clinical pharmacology and therapeutics.
[49] M. E. Goldberg,et al. Direct Myocardial Depressant Effects of Several β-Adrenergic Blocking Agents in the Unanesthetized Atherosclerotic Rabbit , 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[50] P. Manhem,et al. Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol , 1977, European Journal of Clinical Pharmacology.
[51] A. Wood. Cerebrospinal fluid concentration of metoprolol in a hypertensive patient. , 1977, British journal of clinical pharmacology.
[52] P. Lund-johansen,et al. Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension. , 1977, British journal of clinical pharmacology.
[53] W. Nayler,et al. Effect of propranolol, a beta-adrenergic antagonist, on blood flow in the coronary and other vascular fields. , 1967, American heart journal.
[54] C. Regårdh,et al. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. , 2009, Acta pharmacologica et toxicologica.
[55] J. M. Shaw,et al. Nadolol: placental transfer and excretion in the milk of rats. , 1977, Toxicology and applied pharmacology.
[56] B. Folkow,et al. Effects of prolonged treatment with adrenergic beta-receptor antagonists on blood pressure, cardiovascular design and reactivity in spontaneously hypertensive rats (SHR). , 1974, Acta physiologica Scandinavica.
[57] C. Bengtsson. Comparison between metoprolol and propranolol as antihypertensive agents. A double-blind cross-over study. , 2009, Acta medica Scandinavica.
[58] H. Formgren. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. , 1976, British journal of clinical pharmacology.
[59] O. Keyriläinen,et al. Effects of metoprolol in angina pectoris. A subacute study with exercise tests and a long-term tolerability study. , 2009, Acta medica Scandinavica.
[60] S. Taylor,et al. Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment. , 1976, British medical journal.
[61] R. Elofsson,et al. Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. , 1974, Acta pharmaceutica Suecica.
[62] O. Oosthuizen,et al. South African multicentre study of metoprolol and propranolol in essential hypertension. , 1977, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[63] M. Frick,et al. Double-blind titrated-dose comparison of metoprolol and propranolol in the treatment of angina pectoris. , 1976, Annals of clinical research.
[64] R. Newman. Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia. , 1976, British medical journal.
[65] R. Bergstrand,et al. Comparative study of metoprolol and alpha-methyldopa in untreated essential hypertension , 2004, European Journal of Clinical Pharmacology.
[66] D. Adams,et al. The renal circulation in hypertensive disease. , 1976, The American journal of medicine.
[67] L. Tivenius. Effects of muliple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease. , 1976, Scandinavian journal of respiratory diseases.
[68] E. Besterman,et al. An eighteen months' study of the clinical response to metoprolol, a selective beta1-receptor blocking agent, in patients with angina pectoris. , 1976, Postgraduate medical journal.
[69] B. Møller. Letter: Massive intoxication with metoprolol. , 1976, British medical journal.
[70] A. Jäättelä,et al. A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone. , 1976, British journal of clinical pharmacology.
[71] J. M. Shaw,et al. Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: an unusual species difference. , 1978, Xenobiotica; the fate of foreign compounds in biological systems.
[72] J. K. Gibson,et al. Direct and beta adrenergic blocking actions of nadolol (SQ 11725) on electrophysiologic properties of isolated canine myocardium. , 1977, Journal of Pharmacology and Experimental Therapeutics.
[73] Y. Yoon,et al. Preclinical toxicologic evaluation of nadolol, a new β-adrenergic antagonist☆ , 1978 .
[74] B. Hansson,et al. Effect of metoprolol on blood glycerol, free fatty acids, triglycerides and glucose in relation to plasma catecholamines in hypertensive patients at rest and following submaximal work , 1978, European Journal of Clinical Pharmacology.
[75] D. Ward,et al. Glucagon and beta-blocker toxicity. , 1976, British medical journal.
[76] R. Gordon. Initial treatment of the young hypertensive: thiazide diuretic or beta-adrenoreceptor-blocking agent in a single daily dose? , 1976, Clinical science and molecular medicine. Supplement.
[77] C. Regårdh,et al. Clinical Pharmacokinetics of β-Adrenoceptor Blocking Drugs , 1976 .
[78] C. Regårdh,et al. Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. , 2009, Acta pharmacologica et toxicologica.
[79] R. Johansson,et al. Pharmacokinetic studies on the selectiveβ1-receptor antagonist metoprolol in man , 1974, Journal of Pharmacokinetics and Biopharmaceutics.
[80] C. Dollery,et al. Clinical pharmacology of beta‐receptor‐blocking drugs , 1969, Clinical pharmacology and therapeutics.
[81] O. L. Pedersen. Comparison of metoprolol and hydrochlorothiazide as antihypertensive agents , 2004, European Journal of Clinical Pharmacology.
[82] P. Turner,et al. β-Adrenergic Receptor Blocking Drugs in Hyperthyroidism , 2012, Drugs.
[83] H. Waal‐Manning. Experience with β-Adrenoreceptor Blockers in Hypertension , 2012, Drugs.
[84] F. Gobel,et al. Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris. , 1978, British heart journal.
[85] Bramahn . Singh,et al. Effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma , 1976, Clinical pharmacology and therapeutics.